Risk factor
Very high price volatility
Profitability factor
Strong growth
About
BRIM Biotechnology, Inc., a clinical-stage firm, specializes in developing innovative regenerative therapies to address both ophthalmic and degenerative joint conditions. Leading its pipeline is BRM 421, a topical ophthalmic solution designed to treat moderate-to-severe dry eye syndrome, which has successfully completed a Phase 2 clinical trial in the United States. The company's development efforts also encompass BRM 423, currently in Phase 1 clinical trials for severe corneal damage; BRM 424, also in Phase 1, targeting neurotrophic keratitis; and BRM 521, which aims to alleviate and repair tissue damage caused by osteoarthritis. Founded in 2013, BRIM Biotechnology is headquartered in Taipei, Taiwan.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.